Tuesday 16 August 2022 - 04:19
In Business 42 Years - Since 1980
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
A-7337 Acalabrutinib, Free Base, >99%
Synonyms : [ACP196]
Related Terms : [Calquence]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 39
- 38
- 32
- 5,200
- In stock
- 10 mg
- 52
- 50
- 43
- 6,900
- In stock
- 25 mg
- 69
- 67
- 57
- 9,200
- In stock
- 50 mg
- 92
- 90
- 76
- 12,200
- In stock
- 100 mg
- 115
- 112
- 95
- 15,300
- In stock
- 200 mg
- 195
- 191
- 161
- 25,900
- In stock
- 500 mg
- 336
- 329
- 277
- 44,600
- In stock
- 1 g
- 565
- 553
- 467
- 75,000
- In stock
- 2 g
- 885
- 867
- 731
- 117,400
- In stock
- 5 g
- 1,565
- 1,533
- 1,294
- 207,600
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 465.51
- C26H23N7O2
- [1420477-60-6]
Solubility: DMSO.
- Acalabrutinib, also known as ACP-196, is an irreversible Bruton tyrosine kinase (BTK) inhibitor. It binds covalently to Cys481 with improved selectivity and in vivo target coverage. Acalabrutinib inhibited BTK with an IC50 of 3 nM and had improved target specificity over ibrutinib with 323-, 94-, 19-, and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR. Wu J., et al. "Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor." J. Hematol. Oncol. 9: 21 (2016).
- Acalabrutinib avoided major platelet dysfunction in non-Hodgkin lymphoma (NHL) patients associated with ibrutinib treatment. Bye A.P., et al. "Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 1: 2610-2623 (2017).
- In an uncontrolled, phase 1-2, multicenter study, the selective and irreversible BTK inhibitor acalabrutinib demonstrated promising safety and efficacy profiles in patients with relapsed chronic lymphocytic leukemia (CLL), including those with chromosome 17p13.1 deletion. Byrd J.C., et al. "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia." N. Engl. J. Med. 374: 323-332 (2016).
- Acalabrutinib is the active ingredient in the drug product sold under the trade name Calquence®. This drug is currently approved in a least one country for treatment of adult patients with mantle cell lymphoma. NOTE: THE ACALABRUTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT CALQUENCE®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
